Table 2. Disease activity related measures, ASDAS, BASDAI, mSASSS and BASFI in AS patients.
| Total | Female | Male | ||
|---|---|---|---|---|
| n = 307 | n = 62 | n = 245 | P-value | |
| Back pain*# | 2.3 ± 1.9 | 2.7 ± 2.1 | 2.2 ± 1.8 | 0.040 |
| Peripheral joint pain*# | 1.5 ± 1.9 | 1.9 ± 2.1 | 1.3 ± 1.8 | 0.067 |
| Morning stiffness duration*# | 2.3 ± 2.7 | 2.0 ± 2.6 | 2.4 ± 2.7 | 0.344 |
| Patient’s assessment of global health* | 1.6 ± 1.9 | 2.3 ± 2.1 | 1.4 ± 1.8 | 0.004 |
| Fatigue# | 2.8 ± 2.0 | 3.4 ± 2.2 | 2.7 ± 1.9 | 0.021 |
| Tenderness# | 1.3 ± 1.8 | 1.7 ± 2.2 | 1.2 ± 1.7 | 0.103 |
| Degree of morning stiffness# | 2.4 ± 2.2 | 2.2 ± 2.0 | 2.5 ± 2.3 | 0.361 |
| ESR | 12.5 ± 14.9 | 17.6 ± 12.9 | 11.1 ± 15.1 | 0.002 |
| CRP | 0.6 ± 1.6 | 0.4 ± 0.5 | 0.6 ± 1.7 | 0.228 |
| ASDAS-ESR | 1.6 ± 0.8 | 1.9 ± 0.8 | 1.5 ± 0.8 | <0.001 |
| ASDAS-ESR group, n (%) | <0.001 | |||
| <1.3 | 131 (42.7) | 13 (21) | 118 (48.2) | |
| 1.3–2.1 | 108 (35.2) | 24 (38.7) | 84 (34.3) | |
| 2.1–3.5 | 56 (18.2) | 21 (33.9) | 35 (14.3) | |
| ≥3.5 | 12 (3.9) | 4 (6.5) | 8 (3.3) | |
| ASDAS-CRP | 1.5 ± 0.9 | 1.5 ± 0.9 | 1.5 ± 0.9 | 0.972 |
| ASDAS-CRP group, n (%) | 0.414 | |||
| <1.3 | 139 (45.3) | 28 (45.2) | 111 (45.3) | |
| 1.3–2.1 | 104 (33.9) | 17 (27.4) | 87 (35.5) | |
| 2.1–3.5 | 50 (16.3) | 14 (22.6) | 36 (14.7) | |
| ≥3.5 | 14 (4.6) | 3 (4.8) | 11 (4.5) | |
| BASDAI | 2.0 ± 1.5 | 2.4 ± 1.8 | 2.0 ± 1.4 | 0.115 |
| mSASSS | 18.6 ± 22.2 | 6.0 ± 11.4 | 21.8 ± 23.1 | <0.001 |
| BASFI | 1.2 ± 1.7 | 1.1 ± 1.6 | 1.2 ± 1.7 | 0.765 |
Data were shown as mean ± standard deviation unless specified otherwise.
*ASDAS related measures.
#BASDAI related measures.
Abbreviations: ASDAS, ankylosing spondylitis disease activity score; BASDAI, Bath ankylosing spondylitis disease activity index; mSASSS, modified Stoke ankylosing spondylitis spinal score; BASFI, Bath ankylosing spondylitis functional index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.